STARt-001 is the first clinical study to evaluate Marengo’s novel, selective Vβ TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancers Invikafusp alfa, a first-in-class, […]
